Ad is loading...
PLRX
Price
$12.43
Change
-$0.42 (-3.27%)
Updated
Nov 15 closing price
106 days until earnings call
VRNA
Price
$35.66
Change
+$0.29 (+0.82%)
Updated
Nov 15 closing price
101 days until earnings call
Ad is loading...

PLRX vs VRNA

Header iconPLRX vs VRNA Comparison
Open Charts PLRX vs VRNABanner chart's image
Pliant Therapeutics
Price$12.43
Change-$0.42 (-3.27%)
Volume$741.23K
CapitalizationN/A
Verona Pharma
Price$35.66
Change+$0.29 (+0.82%)
Volume$988.18K
CapitalizationN/A
PLRX vs VRNA Comparison Chart
Loading...
PLRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
PLRX vs. VRNA commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLRX is a Sell and VRNA is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (PLRX: $12.43 vs. VRNA: $35.66)
Brand notoriety: PLRX and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PLRX: 172% vs. VRNA: 96%
Market capitalization -- PLRX: $756.41M vs. VRNA: $2.92B
PLRX [@Biotechnology] is valued at $756.41M. VRNA’s [@Biotechnology] market capitalization is $2.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLRX’s FA Score shows that 0 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • PLRX’s FA Score: 0 green, 5 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, VRNA is a better buy in the long-term than PLRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PLRX’s TA Score shows that 5 TA indicator(s) are bullish while VRNA’s TA Score has 3 bullish TA indicator(s).

  • PLRX’s TA Score: 5 bullish, 5 bearish.
  • VRNA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, PLRX is a better buy in the short-term than VRNA.

Price Growth

PLRX (@Biotechnology) experienced а -17.13% price change this week, while VRNA (@Biotechnology) price change was -7.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

PLRX is expected to report earnings on Mar 04, 2025.

VRNA is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($2.92B) has a higher market cap than PLRX($756M). VRNA YTD gains are higher at: 79.376 vs. PLRX (-31.364). VRNA has higher annual earnings (EBITDA): -118.43M vs. PLRX (-181.41M). PLRX has more cash in the bank: 437M vs. VRNA (405M). PLRX has less debt than VRNA: PLRX (60.2M) vs VRNA (122M). PLRX (0) and VRNA (0) have equivalent revenues.
PLRXVRNAPLRX / VRNA
Capitalization756M2.92B26%
EBITDA-181.41M-118.43M153%
Gain YTD-31.36479.376-40%
P/E RatioN/AN/A-
Revenue00-
Total Cash437M405M108%
Total Debt60.2M122M49%
FUNDAMENTALS RATINGS
VRNA: Fundamental Ratings
VRNA
OUTLOOK RATING
1..100
36
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
PROFIT vs RISK RATING
1..100
12
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PLRXVRNA
RSI
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Ad is loading...
PLRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CIREX71.86-0.32
-0.44%
American Funds Capital Income Bldr 529E
PYVAX19.31-0.09
-0.46%
Payden Equity Income Adviser
FCVFX37.21-0.18
-0.48%
Fidelity Advisor Value C
SEQUX193.13-2.48
-1.27%
Sequoia
APITX12.98-0.18
-1.37%
Yorktown Growth L

PLRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PLRX has been loosely correlated with NTLA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if PLRX jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLRX
1D Price
Change %
PLRX100%
-3.27%
NTLA - PLRX
52%
Loosely correlated
-7.61%
RCKT - PLRX
51%
Loosely correlated
-5.67%
BEAM - PLRX
51%
Loosely correlated
-8.59%
ABSI - PLRX
49%
Loosely correlated
-5.80%
INZY - PLRX
48%
Loosely correlated
-8.89%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with VCYT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
+0.82%
VCYT - VRNA
38%
Loosely correlated
-2.97%
AKBA - VRNA
35%
Loosely correlated
-3.76%
KRYS - VRNA
34%
Loosely correlated
-3.75%
INZY - VRNA
34%
Loosely correlated
-8.89%
PLRX - VRNA
34%
Loosely correlated
-3.27%
More